- Home
- JYNT vs ACIU Comparison
JYNT vs ACIU Comparison
Compare JYNT & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JYNT
- ACIU
- Stock Information
- Founded
- JYNT 2010
- ACIU 2003
- Country
- JYNT United States
- ACIU Switzerland
- Employees
- JYNT N/A
- ACIU N/A
- Industry
- JYNT Multi-Sector Companies
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- JYNT Miscellaneous
- ACIU Health Care
- Exchange
- JYNT Nasdaq
- ACIU Nasdaq
- Market Cap
- JYNT 170.1M
- ACIU 189.1M
- IPO Year
- JYNT 2014
- ACIU 2016
- Fundamental
- Price
- JYNT $11.52
- ACIU $2.06
- Analyst Decision
- JYNT Strong Buy
- ACIU Strong Buy
- Analyst Count
- JYNT 2
- ACIU 1
- Target Price
- JYNT $15.50
- ACIU $12.00
- AVG Volume (30 Days)
- JYNT 73.1K
- ACIU 122.5K
- Earning Date
- JYNT 08-07-2025
- ACIU 08-05-2025
- Dividend Yield
- JYNT N/A
- ACIU N/A
- EPS Growth
- JYNT N/A
- ACIU N/A
- EPS
- JYNT N/A
- ACIU N/A
- Revenue
- JYNT $52,789,479.00
- ACIU $32,014,254.00
- Revenue This Year
- JYNT $9.48
- ACIU N/A
- Revenue Next Year
- JYNT $11.15
- ACIU $533.21
- P/E Ratio
- JYNT N/A
- ACIU N/A
- Revenue Growth
- JYNT 71.05
- ACIU 91.20
- 52 Week Low
- JYNT $9.58
- ACIU $1.43
- 52 Week High
- JYNT $15.32
- ACIU $4.26
- Technical
- Relative Strength Index (RSI)
- JYNT 54.97
- ACIU 54.21
- Support Level
- JYNT $11.71
- ACIU $1.94
- Resistance Level
- JYNT $12.27
- ACIU $2.15
- Average True Range (ATR)
- JYNT 0.62
- ACIU 0.16
- MACD
- JYNT -0.01
- ACIU -0.00
- Stochastic Oscillator
- JYNT 46.05
- ACIU 72.22
About JYNT The Joint Corp.
The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The Company has two operating business segments; the Corporate Clinics segment is comprised of the operating activities of the company-owned or managed clinics, and The Franchise Operations segment is comprised of the operating activities of the franchise business unit. The company generates maximum revenue from the Corporate clinic's segment.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.